Radiation and Nuclear Safety Authority, Finland Report issue

Government Phase 4

Organization Overview

First Clinical Trial
2015
NCT02464709
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

STUK - Radiation and Nuclear Safety Authority: Finland

Active Ingredients

Drugs in Phase 4 Trials (2)

aminolevulinic acid (levulan) (1 trial)

methyl aminolevulinate (metvixia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Keratosis (Phase 4)

Keratosis, Actinic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 2